European Pharmacovigilance Congress 2026
EnglishEnglishPanoramica della conferenza
Become sponsor of European Pharmacovigilance Congress 2026, click here
๐๐ EUPV celebrates its 10th anniversary this year!
The European Pharmacovigilance Congress, organized by Pharma Education Center, is recognized as one of the most important and appreciated global pharmacovigilance conferences thanks to its top-tier scientific content.
The high value of this year`s program is assured by the contribution of the key opinion leaders, experts and scientists included in the Scientific Advisory Group (SAG).
In addition, we are delighted to announce the new scientific partnership with the renowned Department of Pharmacological and Biomolecular Sciences of the Milan University (Universitร degli Studi di Milano) and the confirmation of collaboration with the Institute of Pharmacovigilance.
The EUPV Scientific Advisory Group has very clear that pharmacovigilance main pillars are:
โข Safety Science – Regulatory compliance – Operational excellence
โข Implementation of new technologies – Effective communication
All these aspects are reflected in the agenda of this year’s congress.
The EUPV congress gathers PV professionals at all career levels, including key decision makers (e.g. VPs, Executives and Directors) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.
EUPV congress is the forum where all PV stakeholders from all over the world meet and exchange ideas.
PLEASE NOTE:
Ticket options labeled โ+ Visaโ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
ANNUAL EUPV BOOKLET
The 3rd European Pharmacovigilance Congress: speaker abstracts 2019
The 4th European Pharmacovigilance Congress: speaker abstracts 2020
The 5th European Pharmacovigilance Congress: speaker abstracts 2021
The 6th European Pharmacovigilance Congress: speaker abstracts 2022
The 7th European Pharmacovigilance Congress: speaker abstracts 2023
The 8th European Pharmacovigilance Congress: speaker abstracts 2024
The 9th European Pharmacovigilance Congress: speaker abstracts 2025
Published by Sage Journals, visit their website here
Format del congresso
The European Pharmacovigilance Congress 2026 will be a mixed event!
November 18 | Virtual (9.00 – 5.30 pm)
November 19 | Virtual (9.00 – 6.00 pm)
December 3 | Milan* (3.00 – 7.00 pm) + Networking Aperitivo (7.00 – 9.00 pm)
December 4 | Milan* (9.15 – 5.30 pm)
* at NH Milan Congress Centre
NETWORKING APERITIVO December 3 (7.00 – 9.00 pm)
At the conference venue, PEC organizes a Networking Aperitivo that will take place together with interesting workshops. Reserve your place to meet and network with your colleagues and experts: Networking Aperitivo
The intense, scientific interaction between speakers and delegates is a further invaluable plus of the event:
– 27 Topics
– 24 round tables
– 7 virtual parallel sessions
– 1 LECTIO Magistralis
– 3 F2F parallel workshops
Perchรจ partecipare?
- Learn about the latest Pharmacovigilance trends and updates
- Share experiences and solutions at a leading European event
- Forge new collaborations with key decision makers
- Networking through the virtual platform with Pharma Companies Delegates and Speakers
A chi รจ rivolto?
- Pharma, Biotech and Medical Devices Industries
- Pharmacovigilance Associations
- Regulatory Bodies
- CROs and CMOs
- Clinical Research Sites
- Data Management Companies
- Software Development Companies
- University Faculties
- PV Consultant Societies
AGENDA 2026
Find all sessions and their topics in details here: DOWNLOAD BROCHURE
NOVEMBER 18 | VIRTUAL
The ย safety profile of an investigational medicinal product evolves and becoming better defined over time. This session focuses on the latest regulatory developments and expectations.
The session highlights the integration of advanced approaches, from AIโdriven modelling and realโworld evidence to New Approach Methodologies (NAMs), to bridge in vitro insights and human outcomes. Together, these innovations are shaping proactive, dataโdriven strategies to predict, prevent, and ultimately protect patient safety.
Gene therapies and other advanced therapies are transforming the treatment landscape for rare diseases, offering unprecedented opportunities for patients with high unmet medical needs. However, these innovations also present unique safety challenges that require new approaches to risk assessment, and long-term safety evaluation. This session explores emerging safety considerations across gene therapies (including antisense oligonucleotides) and ATMPs.
Pharmacovigilance outside the EU presents a highly dynamic regulatory landscape, shaped by local publicโhealth priorities and evolving legal frameworks.
This session will take us across Asia and Africa, highlighting how global principles translate into regional practice. Pharmacovigilance systems must be reviewed to ensure alignment with these requirements.
The era of AI has paved the road to completely new possibilities that would have been unthinkable only a few years ago. This session looks into the near future by discussing the use of artificially generated datasets that mimic real drug-safety data.
While the methodologies to assess the risks of medicinal products are common throughout all therapeutic areas, each of them requires specific considerations. This session focuses on important safety aspects that have required investigation for new products indicated in inflammatory disorders.
Early Access and Compassionate Use Programs provide patients with serious or life-threatening diseases access to promising therapies before formal approval. While these programs offer important treatment opportunities, they also require robust safety surveillance and compliance frameworks to protect patients and ensure appropriate benefit-risk evaluation.
Pharmacovigilance is a science that strives to have medicines with the best possible benefit-risk balance. It is based on detailed regulations and guidelines, therefore its link with regulatory affairs is apparent. However, pharmacovigilance professionals donยดt always consider the economic value the outcome of their work brings to patients and society and the impact it can have on the healthcare system. Strengthening the links between pharmacovigilance, regulatory affairs, and health technology assessment can help us take a more holistic view of the value of medicines and the decision surrounding their use.
SAFETY OF DRUGS USED IN HEPATIC RARE DISEASES (A DISCUSSION AT THE EUROPEAN PARLIAMENT)
A unique opportunity to hear firstโhand about a discussion held at one of Europeโs most important institutions, presented directly by the speaker involved sharing information that can be publicly disclosed.
NOVEMBER 19 | VIRTUAL
The pharmacovigilance landscape continues to evolve as new regulations, guidance, and industry standards reshape safety practices worldwide. From CIOMS initiatives to updates in Good Pharmacovigilance Practices, these changes bring both challenges and opportunities to strengthen patient safety and improve risk management.
As adoption of artificial intelligence accelerates, regulators and industry are gaining increasing experience in balancing innovation with compliance, transparency, and patient safety. Learn from the regulators how they have implemented AI in their processes and their expectations on how it should be implemented.
As combination products become increasingly complex, ensuring effective safety oversight requires close collaboration across regulatory, quality, and pharmacovigilance functions. This session explores the roles of key stakeholders and highlights best practices for optimizing cross-functional communication to strengthen patient safety throughout the product lifecycle.
AI has been a key buzzword in pharmacovigilance over recent years, yet its practical implementation remains a challenge. This session focuses on methodologies and realโworld examples that illustrate how AI can be effectively implemented in pharmacovigilance practice.
This session aims to explore the importance of integrating patientsโ perspectives into pharmacovigilance. Patientsโ lived experiences provide valuable real-world evidence on the benefits and risks of medicines, contributing to the identification and better understanding of safety issues. The session will highlight the importance of collaboration among patients, healthcare professionals, regulators, and industry to advance a more patient-centered approach to medicine safety.
An overview of pharmacovigilance requirements across key nonโEU regions, with a focus on the UK and the Americas. Learn how MHRA requirements are evolving and Latin America regulations, including Brazilian ones, shape regional safety obligations and reporting requirements.
Pharmacovigilance professionals are often not fully aware of closely related disciplines, such as cosmetics and nutraceutical safety, and of the potential impact these products may have on drug safety. This session aims to provide an overview of these areas.
All pharmacovigilance stakeholders, including regulators, are continuously enhancing their digital tools. This session enables participants to stay up to date with changes in EMA systems, such as EudraVigilance and the Clinical Trials Information System (CTIS).
Ecopharmacovigilance, focuses on the environmental impact of pharmaceuticals across their lifecycleand is attracting increasing attention. New initiatives are being developed to collect data, monitor and evaluate how medicines affect the ecosystem.
DECEMBER 3 | MILAN
The aim of pharmacovigilance is to identify the most important risks associated with a medicinal product and to minimise them, ensuring a positive benefitโrisk balance. This session provides insights into how to establish an effective risk management system, including in particularly challenging situations.
The unprecedented volume of patient data available today offers new opportunities to transform data into meaningful evidence. Pharmacoepidemiology and realโworld evidence play a central role in identifying, quantifying, and characterizing risks, supporting more informed and robust regulatory decisionโmaking.
Many of us talk about AI without realizing it encompasses a range of different technologies, each with distinct characteristics, advantages, and limitations. This session introduces the fundamentals of AI and illustrates its practical application through a realโlife example in case processing.
When evaluating a new technology, we should not consider it in isolation. Even the smartest machine or the latest technology is fit for purpose to the extent it is able to accommodate human oversight and integrate with human characteristics and needs. BY IVIGEE
DECEMBER 4 | MILAN
Pharmacovigilance operates in a rapidly evolving environment shaped by growing data volumes, advancing science and technology, and increasing regulatory expectations. While these changes bring challenges, they also create opportunities to enhance efficiency, strengthen decision-making, and ultimately improve patient outcomes.
Pharmacovigilance is grounded in scientific disciplines such as biology and pharmacology, which underpin medicine safety from nonโclinical research through clinical development and shape risk management strategies. This session offers realโworld insights into the value of applying scientific principles to drug safety.
Navigating pharmacovigilance requirements in Saudi Arabia/GCC requires a thorough understanding of the evolving expectations of regional authorities. This workshop reviews key PV obligations, inspection considerations, and practical strategies for building resilient, inspection-ready pharmacovigilance systems.
Aya Anis, PV Vendor & Operations Manager | Baupharma
Zaina Bakir, KSA QPPV / PV Director | Baupharma
Applying artificial intelligence to realโworld evidence is one of todayโs most prominent topics. But what do regulators think? This session offers a rare opportunity to hear directly from PRAC members and leading scientists on how AI can be used to transform realโworld data into robust evidence for signal detection and management.
One year after the implementation of Commission Implementing Regulation (EU) 2025/1466, this workshop will examine key lessons learned, implementation challenges, and emerging opportunities in pharmacovigilance operations. Through expert insights and interactive discussions, participants will explore compliance strategies, operational adaptations, and approaches to maintaining patient safety in the evolving regulatory landscape. Featured presenters:
- Elena Alcaraz , EU/UK QPPV, Strategic Advisor | PrimeVigilance
- Mercedina del Papa, EU/UK QPPV, Strategic Advisor | PrimeVigilance
The session that traditionally closes the EU PV Congress is also one of its most important. Compliance -and the successful outcome of audits and inspections- represents the true โlicense to operateโ in pharmacovigilance and across the pharmaceutical industry.
Scientific Advisory Group 2026
Felix Arellano
Owner | Arellano Risk Management, GmbH, Switzerland
Ayman Ayoub
Vice President Safety Evaluation and Risk Management | GSK
Mattia Calissano
VP, Medical | SSI Strategy
Gian Nicola Castiglione
Pharmacovigilance Consultant, SIMeF ETS Board member, Past Head of Global Pharmacovigilance and EU-UK QPPV, Pharmacovigilance trainer
Manuela Casula
Associate Professor at Department of Pharmacological and Biomolecular Sciences | University of Milan
Mircea Ciuca
Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance
Giovanni Furlan
Head Medical Safety Operations | Sandoz
Calin A. Lungu
DDCS S.A., CEO
Hrvoje Maฤek
VP Pharmacovigilance Services | Clingen
Valentina Mancini
Head of Drug Safety, QPPV | Shionogi Europe
Arduino Mangoni
Strategic Professor in Clinical Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
Jan Petracek
CEO |ย iVigee, Director | Institute of Pharmacovigilance
Marco Sardella
Chief Pharmacovigilance Officer & EU-UK QPPV| ADIENNE Pharma & Biotech – Chairperson of the Congress
Ivana ล utalo
Innovative Products, Business Unit Lead / EU QPPV / LCPPV Croatia | PrimeVigilance Ltd.
Elena Prokofyeva
Head of Clinical Trial Safety Unit, Department of Pharmacovigilance, DG POST | FAMHP – Belgium
Sophia Trantza
Senior Pharmacovigilance Expert, former PRAC Member Greece
SPEAKERS 2026 IN PROGRESS
Ana Sofia Martins
PRAC Member | INFARMED, I.P. – Portugal
Elena Giovani
Head of the GVP Inspection Office | AIFA (Tbc)
Amelia Cupelli
Pharmacologist, Italian Medicines Agency (AIFA), EMA PRAC Member, Italy
Pilar Rayรณn
PRAC – AEMPS Spain
Lembit Rรคgo
Secretary-General | Council for International Organizations of Medical Sciences (CIOMS) – Switzerland
Aurora Marรญa Rojo Sanchรญs
Head of GCP &GVP Inspectorate | Spanish Agency of Medicines and Medical Devices (AEMPS)
David Sullivan
Vigilance Collaborations Specialist | MHRA
Ursula Kirchmayer
Pharmacoepidemiologist at the Department of Epidemiology | Lazio regional health service
Fazil Afzal
Senior Medical Assessor at Medicines and Healthcare products Regulatory Agency (MHRA) – Uk (tbc)
Michelle English
Good Clinical Practice and Pharmacovigilance Inspector with the Health Products Regulatory Authority – Ireland
Claudia Schaffer
Head of ICSR Management | Merck Healthcare KGaA – Germany
Oanh Dang
Regulatory Science and Applied Research Lead | Food and Drug Administration (FDA) – USA
Marko Korenjak
President of the European Liver Patients ( ELPA), member of HMA management board of EMA – Slovenia
Maia Uuskรผla
Head of the Department of Post-Authorisation Safety | State Agency of Medicines, Estonia
Zane Neikena
EMA PRAC Member from Latvia, Pharmacovigilance expert
Jens-Ulrich Stegmann
Senior Vice President, Head Clinical Safety and Pharmacovigilance and EU QPPV | GSK – Belgium
Jonathan Sutch
Principal Technical Specialist & Scheme Manager | BSI Group – UK
Axelle Mutezinkwano
Pharmacovigilance Analyst Team Lead | Rwanda Food and Drugs Authority
Annalisa Capuano
Full Professor of Pharmacology – Department of Experimental Medicine |ย University of Campania โL. Vanvitelliโ – Italy
Kaori Nomura
Associate Professor | Fukushima Medical University – Japan
Andrew Bate
VP, Head of Safety Innovation & Analytics | GSK – Uk
Salvo Leone
General Director | Patientโs Association AMICI, Italy
Emanuele Lettieri
Full Professor | Politecnico of Milan, Italy
Margherita D’Antuono
Deputy Chief Manager – QPPV | Piramal Critical Care
Vicky Edwards
Vice President, Cross Therapeutic Area Safety Science, Global Patient Safety| Abbvie – UK
Anna Lombardo
Researcher | Istituto di Ricerche Farmacologiche Mario Negri IRCCS – Italy
Giovanna Paolone
Associate Professor of Pharmacology – Department of diagnostics and public health | University of Verona – Italy
Flavia Meyer
Researcher / Pharmacoepidemiology and Pharmacosurveillance Unit, National Centerm for Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy
Emanuela Corsini
Professor of Toxicology at Department of Pharmacological and Biomolecular Sciences โRodolfo Paoletti’ | University of Milan
Barbara De Bernardi
EU & UK Pharmacovigilance Qualified Person, VP, Head of Global QPPV Office Worldwide Medical & Safety | Pfizer – Italy
Helaine Capucho
Access Director | Interfarma – Brazil
Ahmed Diaa Eldin
CEO | Baupharma – Czech Republic
Josรฉ Alberto Ayala Ortiz
CEO, QPPV, Pharmacovigilance consultant | PVpharm
Marie-Laure Kurzinger
Associate VP, Head of Pharmacoepidemiology -General Medicines, Pharmacovigilance and Patient Safety | Sanofi – France
Rajat Mohindra
Principal Medical Director Personalized Healthcare Safety | F.Hoffmann – La Roche – Switzerland
Adrian Roth
Principal Scientific Director Precision Safety | Roche – Switzerland
Ilaria Grisoni
Exec. Dir., Head of International QPPV Office, EEA QPPV | Jazz Pharmaceuticals – Italy
Michael Von Forstner
Managing Director | Mesa Laubela Consulting – Switzerland
Yiannoula Koulla
Patient Expert, Member of the EMA PRAC
Klaudija Marijanovic Barac
Associate VP, EU QPPV Deputy | Eli Lilly Hrvatska d.o.o. – Croatia
Daniela Gramaglia
Associate Director Medical Device Safety | Bayer
Alberto Gramaccioli
Director of Quality Management and Inspection | Pfizer
Maria Beatrice Panico
Chief Medical Officer | Scendea – UK
Maddalena Lino
Safety Risk Lead, Sr Director | Pfizer – Italy
Daniela Marcozzi
Head of Corporate Clinical Safety, Pharmacovigilance and R&D Compliance – Company Representative for Competent Health Authorities | Fidia Farmaceutici – Italy
Mercedina del Papa
EU QPPV, UK QPPV, Strategic Advisor | PrimeVigilance
Elena Alcaraz
EU QPPV, UK QPPV, Strategic Advisor | PrimeVigilance
Bogdana Ioana Balas
Group Medical Director | F. Hoffmann – La Roche Ltd – Switzerland
Lucia Biagiotti
Safety & Vigilance – BU Director | PL Italia
Alexandru Mihai Bica
Head of Early Development Safety | CSL Behring – Germany
Mehmet Burcu
Sr. Director, Epidemiology | Merck & Co., Inc., Rahway –ย NJ, USA
Marie-Pierre Caby-Tosi
Executive Director, EEA/UK QPPV, Head of EMEA PV Clinical Safety & Pharmacovigilance | Moderna – France
Katerina Georgousaki
Regulatory Affairs Manager | ELAIS-Unilever Hellas S.A. – Greece
Ramona Grigorescu
Senior Medical Monitor | Danone – Holland
Sadia Halim
SERM Medical Director | GSK – Uk
Mohamed Ali Kotal
EU-QPPV & Head QPPV Office | Sandoz – Germany
Daniel Hyde
Associate Director, Pharmacovigilance Operations | Clinigen – UK
Wojciech Maseลbas
SERM Medical Director | Gsk – Poland
James Milligan
Vice President | SSI – UK
Darmendra Ramcharran
Sr Director, Safety & Quantitative Innovation | GSK – USA
Hendrik ล uvalov
PhD Student in Health Informatics | University of Tartu – Estonia
Alina Tudor
Senior Director, Pharmacovigilance | Kyowa Kirin International plc. – UK
Hans-Joerg Roemming
Executive Director, Head of RQS Information, Systems & Insights | Merck Healthcare KGaA – Germany
Aya Anis
MSc. PV. Diploma, Egypt QPPV – PV Director | Baupharma – Czech Republic
Zaina Bakir
PharmD, RPh, Certified PV Professional, KSA QPPV & PV Director | Baupharma – Czech Republic
Serban Ghiorghiu
Vice President, Clinical Development, Late Development Oncology R&D | AstraZeneca
Anette Kirstine Stark
Independent Scientific Expert | PRAC, EMA – Denmark
Natasha Mihajlovic
Chief AI Compliance Officer | Yeza.ai; Managing Director | NostraPharma
MEDIA PARTNER/COLLABORATIONS/SPONSORS 2026 – in progress
Sage Publishing
Scientific Media Partner
Sage Publishing
Scientific Media Partner
Published by Sage Publishing, Therapeutic Advances in Drug Safety (Impact Factor: 3.4) is an international peer-reviewed Open Access journal, delivering the highest quality original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.
As the official Media Partner of the European Pharmacovigilance Congress, Therapeutic Advances in Drug Safety will be publishing an online abstract supplement which will be free to access online.
For more information:
E-mail: shasha.sharief@sagepub.co.uk
Twitter: @TADrugSafety
Visita il sito »
Institute of Pharmacovigilance
Collaboration
Institute of Pharmacovigilance
Collaboration
Founded in 2015, the Institute of Pharmacovigilance (IPV) is a not-for-profit, non-governmental global organization with a clear goal โ to elevate the pharmacovigilance industry by competency and seniority certification.
In 2020, IPV partnered with the International Society of Pharmacovigilance (ISoP) to develop the Global Pharmacovigilance Professional Certification (GPPC), creating a globally recognized standard for PV professionals. The certification works with competency standards including knowledge, skills and attitudes suitable for every role in pharmacovigilance.
Committed to continuous innovation, IPV regularly updates its programs to reflect the latest advancements, ensuring certified professionals have practical knowledge and skills they can apply in their jobs immediately.
Visita il sito »
Universitร degli Studi di Milano – Dipartimento di Scienze Farmacologiche e Biomolecolari
Scientific Partnership
Universitร degli Studi di Milano – Dipartimento di Scienze Farmacologiche e Biomolecolari
Scientific Partnership
Ilย Dipartimento di Scienze Farmacologiche e Biomolecolari “Rodolfo Paoletti”ย (DiSFeB), nominato Dipartimento di Eccellenza 2023-2027, nasce il 27 aprile 2012 dallโaggregazione di settori scientifico disciplinari con comuni interessi di ricerca scientifica di alto profilo, e assicura unโequilibrata valorizzazione di tutti i settori scientifico-disciplinari che vi afferiscono. Il DiSFeB mira a consolidare il suo ruolo chiave nelleโฏattivitร didattiche eโฏdiโฏricerca, e a rinnovare il suo portfolio diโฏcompetenze tecnico-scientifiche a beneficio della societร , contribuendo nel campo delle scienze biologiche applicate alla salute umana, alla prevenzione delle malattie e alla progettazione di farmaci e prodotti per la salute.
Visita il sito »
Baupharma
Silver Sponsor
Baupharma
Silver Sponsor
Baupharma, headquartered in Prague, is a premier pharmaceutical service provider with over 25 years of industry experience. Our international team offers comprehensive servicesโincluding pharmacovigilance, regulatory affairs, medical writing, batch release and distribution, translations, and clinical researchโacross the EU, MENA region, CIS, Africa, USA, LATAM, and beyond. With offices in Czech Republic, Saudi Arabia, UAE and Egypt, we ensure efficient project management and collaboration, delivering tailored solutions that meet the unique needs of each market.
Visita il sito »
Eureka InfoMed
Exhibitor
Eureka InfoMed
Exhibitor
Eureka InfoMed โ Your Team to Growth
We make Pharmacovigilance work โ reliably, efficiently, and with purpose.
Eureka InfoMed is a trusted partner delivering endโtoโend operational support across Pharmacovigilance, Medical Information, and Quality.
We combine operational excellence with a pragmatic, partnershipโdriven approach to turn complexity into compliant, efficient, and scalable processes.
Within these areas, we support pharmaceutical and biotech companies through services including Quality Management Systems, Quality Assurance activities, and Pharmacovigilance audits, helping them strengthen compliance, mitigate risk, and optimize operations in a constantly evolving regulatory environment.
We donโt believe in oneโsizeโfitsโall solutions.
Whether you are building, strengthening, or transforming your Pharmacovigilance organization, Eureka InfoMed works side by side with you, acting as an extension of your team and providing expertise that grows with your needs and strategic objectives.
Visita il sito »
Insuvia
Exhibitor
Insuvia
Exhibitor
Insuvia is designed to act as a pharmacovigilance unit for pharmaceutical companies in those countries and regions, where they have no internal structures or decide to focus their resources on commercial activities. In this context, we provide the regional EU and country-level expertise to solve all pharmacovigilance challenges that pharmaceutical companies encounter while commercializing their products.
Visita il sito »
iVigee
Platinum Sponsor
iVigee
Platinum Sponsor
iVigee is a leading pharmacovigilance services and technology company focused on creating simple, powerful, and elegant drug safety solutions that span the entire drug safety life cycle.
We combine years of experience with the latest innovative AI technologies to create the โinstant pharmacovigilance departmentโ, deployable anywhere, on-demand.
Our teams support clients around the world with progressive pharmacovigilance and data management requirements from our strategic bases in Central Europe and the US East Coast.
iVigee: Simple. Powerful. Elegant.
Visita il sito »
MakingLife
Media Partner
MakingLife
Media Partner
MakingLife is a publishing house and communications agency specializing in the pharmaceutical sector. It combines editorial expertise with strategic communication to provide high-value scientific content for B2B audiences. Through magazines (paper and digital) and digital platforms, such as the MakingConnect community, MakingLife supports pharmaceutical companies and their supply chain in improving visibility and promoting innovation. Its multidisciplinary team combines scientific accuracy, creative storytelling and market knowledge to design communication tools. Furthermore, through MakingEducation, MakingLife offers its customers a training service dedicated to the pharma sector.
Visita il sito »
Max Application
Exhibitor
Max Application
Exhibitor
SafetyDrugs, developed by Max Application, an Abacus company, is a pharmacovigilance safety database managing the lifecycle of ICSRs from clinical trials and post-marketing sources. Designed in compliance with ICH E2B(R3), GVP and GDPR, it meets EMA, FDA and MHRA requirements. The platform enables automated case transmission and regulatory reporting (PSUR, PBRER, DSUR), ensuring data integrity, inspection readiness and full compliance. The offering is completed by the Business Intelligence module for Signal Detection and by the newly developed Chronisia, which automatically calculates regulatory deadlines (e.g. PSUR, RMP, MA renewal) enables task assignment and reduces risk of delays and non-compliance.
Visita il sito »
PrimeVigilance
Gold Plus Sponsor
PrimeVigilance
Gold Plus Sponsor
PrimeVigilance, an Ergomed company, has grown to become the leading Pharmacovigilance specialist company, delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from our operational hubs based in Europe, the USA, and Japan. Our extensive experience enables us to offer a comprehensive, top-quality, cost-effective, and innovative safety solution. Our flexible approach, tailor-made to work with clients, allows us to deliver the services that meet your clinical and post-marketing needs. PrimeVigilance provides pharmacovigilance solutions to over 300 clients who distribute their products worldwide. PrimeVigilance manages a global Pharmacovigilance system with a choice of leading drug safety databases, stretching to more than 100 countries.
Visita il sito »
ProductLife Group
Exhibitor
ProductLife Group
Exhibitor
ProductLife Groupโs mission is to improve human health by delivering regulatory compliance services that support the safe and effective use of healthcare products and solutions.
For more than 30 years, PLG has supported clients throughout the entire product lifecycle, combining local expertise with a global reach spanning more than 150 countries. The Group provides consulting and outsourcing services across regulatory affairs, quality and compliance, market access, pharmacovigilance, and medical information, covering both established products and innovative therapeutics and diagnostics.
Committed to continuously improving the value delivered to patients and customers, PLG fosters long-term partnerships built on innovation, flexibility, and cost efficiency.
Visita il sito »
PVpharm
Gold Sponsor
PVpharm
Gold Sponsor
Pharmacovigilance, Clinical Safety, Regulatory and Quality Solutions for the pharmaceutical industry.
PVpharm provides services to Marketing Authorisation Holders, Sponsors of Clinical Trials and other Life science service providers.
Our objective is to help the Pharmaceutical industry to comply with Pharmacovigilance, Clinical safety, Regulatory and Quality requirements. We provide global, professional, quick, and flexible solutions to complex, specialized needs.
Our specialities include Pharmacovigilance and Clinical Safety services, Regulatory affairs, Medical Services, EU-QPPV and Local contact person for pharmacovigilance, Pharmacovigilance and GCP Audits, EudraVigilance compliance, CTIS support, Pharmacovigilance training, including EVWeb and XEVMPD (eXtended EudraVigilance Medicinal Product Dictionary) training, Signal Detection and Signal Management using EVDAS, IDMP implementation preparation, and data management.
We provide services for drugs, devices, veterinary, food supplements and cosmetics.
We do also provide GxP support and provide GMP specialized audits.
Visita il sito »
Diventa sponsor
Don’t miss the chance to be a European Pharmacovigilance Congress 2026 sponsor!
Contact us to learn about our sponsorship packages, you will have the opportunity to:
โข Deliver a talk in person or online
โข Conduct a parallel session during the day in Milan
โข Network and connect with your target customers
Check out our sponsorship opportunities here:ย Become EUPV Sponsor
Sede del congresso
Step 1
Onย November 18-19ย the event will beย VIRTUAL to grant you the possibility of joining the conference even from your office or home, wherever you may be. We have organized a true virtual location, a space where you will be able to:
- Follow the live streaming of the congress, listen to experts and opinion makers and be informed about latest trends and technological breakthroughs in drug safety
- Visit theย VIRTUAL EXHIBITION AREAย and all the stands of our sponsors
- Join Q&A times and round tables to discuss the current hot topics in the field
- Chat with our sponsors and learn about new technologies and services to ease your daily work and increase the performance
Step 2
Letโs finally meet face to face in Milan on December 3-4! A great chance to meet in person the EUPV experts and colleagues. A great chance to meet in person the EUPV experts and colleagues. The conference will be hosted in the wonderful spaces of NH Milano Congress Centre, in Assago, Milan.
NETWORKING APERITIVO December 3, 2026 (NH Milano Congress Centre, in Assago, Milan)
–> If you would like to attend the Networking Aperitivo, please save your spot here: Networking Aperitivo
PLEASE NOTE:
Ticket options labeled โ+ Visaโ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
Arrivare in aereo
From Malpensa Airport:
-
- take the bus to the central station, then the subway towards Assago Milanofiori Forum
- take the express train from Malpensa to the Cadorna station, then the Green subway in the direction of Assago Milanofiori Forum.
From Linate Airport:
take the bus to San Babila station, then the subway towards Assago Milanofiori Forum.
Arrivare in treno
From Centrale or Cadorna train station, take green line subway to Assago Milanofiori Forum.
Arrivare in tram
From Piazza del Duomo:
take the red subway line towards RHO FIERAMILANO and change at CADORNA. Take the green line towards ASSAGO MILANOFIORI FORUM and get off at the Assago Milanofiori Forum stop. Walk for about 7 minutes to reach the hotel.
Edizioni precedenti
Panoramica della conferenza
Become sponsor of European Pharmacovigilance Congress 2026, click here
๐๐ EUPV celebrates its 10th anniversary this year!
The European Pharmacovigilance Congress, organized by Pharma Education Center, is recognized as one of the most important and appreciated global pharmacovigilance conferences thanks to its top-tier scientific content.
The high value of this year`s program is assured by the contribution of the key opinion leaders, experts and scientists included in the Scientific Advisory Group (SAG).
In addition, we are delighted to announce the new scientific partnership with the renowned Department of Pharmacological and Biomolecular Sciences of the Milan University (Universitร degli Studi di Milano) and the confirmation of collaboration with the Institute of Pharmacovigilance.
The EUPV Scientific Advisory Group has very clear that pharmacovigilance main pillars are:
โข Safety Science – Regulatory compliance – Operational excellence
โข Implementation of new technologies – Effective communication
All these aspects are reflected in the agenda of this year’s congress.
The EUPV congress gathers PV professionals at all career levels, including key decision makers (e.g. VPs, Executives and Directors) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.
EUPV congress is the forum where all PV stakeholders from all over the world meet and exchange ideas.
PLEASE NOTE:
Ticket options labeled โ+ Visaโ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
ANNUAL EUPV BOOKLET
The 3rd European Pharmacovigilance Congress: speaker abstracts 2019
The 4th European Pharmacovigilance Congress: speaker abstracts 2020
The 5th European Pharmacovigilance Congress: speaker abstracts 2021
The 6th European Pharmacovigilance Congress: speaker abstracts 2022
The 7th European Pharmacovigilance Congress: speaker abstracts 2023
The 8th European Pharmacovigilance Congress: speaker abstracts 2024
The 9th European Pharmacovigilance Congress: speaker abstracts 2025
Published by Sage Journals, visit their website here
Format del congresso
The European Pharmacovigilance Congress 2026 will be a mixed event!
November 18 | Virtual (9.00 – 5.30 pm)
November 19 | Virtual (9.00 – 6.00 pm)
December 3 | Milan* (3.00 – 7.00 pm) + Networking Aperitivo (7.00 – 9.00 pm)
December 4 | Milan* (9.15 – 5.30 pm)
* at NH Milan Congress Centre
NETWORKING APERITIVO December 3 (7.00 – 9.00 pm)
At the conference venue, PEC organizes a Networking Aperitivo that will take place together with interesting workshops. Reserve your place to meet and network with your colleagues and experts: Networking Aperitivo
The intense, scientific interaction between speakers and delegates is a further invaluable plus of the event:
– 27 Topics
– 24 round tables
– 7 virtual parallel sessions
– 1 LECTIO Magistralis
– 3 F2F parallel workshops
Perchรจ partecipare?
- Learn about the latest Pharmacovigilance trends and updates
- Share experiences and solutions at a leading European event
- Forge new collaborations with key decision makers
- Networking through the virtual platform with Pharma Companies Delegates and Speakers
A chi รจ rivolto?
- Pharma, Biotech and Medical Devices Industries
- Pharmacovigilance Associations
- Regulatory Bodies
- CROs and CMOs
- Clinical Research Sites
- Data Management Companies
- Software Development Companies
- University Faculties
- PV Consultant Societies
AGENDA 2026
Find all sessions and their topics in details here: DOWNLOAD BROCHURE
NOVEMBER 18 | VIRTUAL
The ย safety profile of an investigational medicinal product evolves and becoming better defined over time. This session focuses on the latest regulatory developments and expectations.
The session highlights the integration of advanced approaches, from AIโdriven modelling and realโworld evidence to New Approach Methodologies (NAMs), to bridge in vitro insights and human outcomes. Together, these innovations are shaping proactive, dataโdriven strategies to predict, prevent, and ultimately protect patient safety.
Gene therapies and other advanced therapies are transforming the treatment landscape for rare diseases, offering unprecedented opportunities for patients with high unmet medical needs. However, these innovations also present unique safety challenges that require new approaches to risk assessment, and long-term safety evaluation. This session explores emerging safety considerations across gene therapies (including antisense oligonucleotides) and ATMPs.
Pharmacovigilance outside the EU presents a highly dynamic regulatory landscape, shaped by local publicโhealth priorities and evolving legal frameworks.
This session will take us across Asia and Africa, highlighting how global principles translate into regional practice. Pharmacovigilance systems must be reviewed to ensure alignment with these requirements.
The era of AI has paved the road to completely new possibilities that would have been unthinkable only a few years ago. This session looks into the near future by discussing the use of artificially generated datasets that mimic real drug-safety data.
While the methodologies to assess the risks of medicinal products are common throughout all therapeutic areas, each of them requires specific considerations. This session focuses on important safety aspects that have required investigation for new products indicated in inflammatory disorders.
Early Access and Compassionate Use Programs provide patients with serious or life-threatening diseases access to promising therapies before formal approval. While these programs offer important treatment opportunities, they also require robust safety surveillance and compliance frameworks to protect patients and ensure appropriate benefit-risk evaluation.
Pharmacovigilance is a science that strives to have medicines with the best possible benefit-risk balance. It is based on detailed regulations and guidelines, therefore its link with regulatory affairs is apparent. However, pharmacovigilance professionals donยดt always consider the economic value the outcome of their work brings to patients and society and the impact it can have on the healthcare system. Strengthening the links between pharmacovigilance, regulatory affairs, and health technology assessment can help us take a more holistic view of the value of medicines and the decision surrounding their use.
SAFETY OF DRUGS USED IN HEPATIC RARE DISEASES (A DISCUSSION AT THE EUROPEAN PARLIAMENT)
A unique opportunity to hear firstโhand about a discussion held at one of Europeโs most important institutions, presented directly by the speaker involved sharing information that can be publicly disclosed.
NOVEMBER 19 | VIRTUAL
The pharmacovigilance landscape continues to evolve as new regulations, guidance, and industry standards reshape safety practices worldwide. From CIOMS initiatives to updates in Good Pharmacovigilance Practices, these changes bring both challenges and opportunities to strengthen patient safety and improve risk management.
As adoption of artificial intelligence accelerates, regulators and industry are gaining increasing experience in balancing innovation with compliance, transparency, and patient safety. Learn from the regulators how they have implemented AI in their processes and their expectations on how it should be implemented.
As combination products become increasingly complex, ensuring effective safety oversight requires close collaboration across regulatory, quality, and pharmacovigilance functions. This session explores the roles of key stakeholders and highlights best practices for optimizing cross-functional communication to strengthen patient safety throughout the product lifecycle.
AI has been a key buzzword in pharmacovigilance over recent years, yet its practical implementation remains a challenge. This session focuses on methodologies and realโworld examples that illustrate how AI can be effectively implemented in pharmacovigilance practice.
This session aims to explore the importance of integrating patientsโ perspectives into pharmacovigilance. Patientsโ lived experiences provide valuable real-world evidence on the benefits and risks of medicines, contributing to the identification and better understanding of safety issues. The session will highlight the importance of collaboration among patients, healthcare professionals, regulators, and industry to advance a more patient-centered approach to medicine safety.
An overview of pharmacovigilance requirements across key nonโEU regions, with a focus on the UK and the Americas. Learn how MHRA requirements are evolving and Latin America regulations, including Brazilian ones, shape regional safety obligations and reporting requirements.
Pharmacovigilance professionals are often not fully aware of closely related disciplines, such as cosmetics and nutraceutical safety, and of the potential impact these products may have on drug safety. This session aims to provide an overview of these areas.
All pharmacovigilance stakeholders, including regulators, are continuously enhancing their digital tools. This session enables participants to stay up to date with changes in EMA systems, such as EudraVigilance and the Clinical Trials Information System (CTIS).
Ecopharmacovigilance, focuses on the environmental impact of pharmaceuticals across their lifecycleand is attracting increasing attention. New initiatives are being developed to collect data, monitor and evaluate how medicines affect the ecosystem.
DECEMBER 3 | MILAN
The aim of pharmacovigilance is to identify the most important risks associated with a medicinal product and to minimise them, ensuring a positive benefitโrisk balance. This session provides insights into how to establish an effective risk management system, including in particularly challenging situations.
The unprecedented volume of patient data available today offers new opportunities to transform data into meaningful evidence. Pharmacoepidemiology and realโworld evidence play a central role in identifying, quantifying, and characterizing risks, supporting more informed and robust regulatory decisionโmaking.
Many of us talk about AI without realizing it encompasses a range of different technologies, each with distinct characteristics, advantages, and limitations. This session introduces the fundamentals of AI and illustrates its practical application through a realโlife example in case processing.
When evaluating a new technology, we should not consider it in isolation. Even the smartest machine or the latest technology is fit for purpose to the extent it is able to accommodate human oversight and integrate with human characteristics and needs. BY IVIGEE
DECEMBER 4 | MILAN
Pharmacovigilance operates in a rapidly evolving environment shaped by growing data volumes, advancing science and technology, and increasing regulatory expectations. While these changes bring challenges, they also create opportunities to enhance efficiency, strengthen decision-making, and ultimately improve patient outcomes.
Pharmacovigilance is grounded in scientific disciplines such as biology and pharmacology, which underpin medicine safety from nonโclinical research through clinical development and shape risk management strategies. This session offers realโworld insights into the value of applying scientific principles to drug safety.
Navigating pharmacovigilance requirements in Saudi Arabia/GCC requires a thorough understanding of the evolving expectations of regional authorities. This workshop reviews key PV obligations, inspection considerations, and practical strategies for building resilient, inspection-ready pharmacovigilance systems.
Aya Anis, PV Vendor & Operations Manager | Baupharma
Zaina Bakir, KSA QPPV / PV Director | Baupharma
Applying artificial intelligence to realโworld evidence is one of todayโs most prominent topics. But what do regulators think? This session offers a rare opportunity to hear directly from PRAC members and leading scientists on how AI can be used to transform realโworld data into robust evidence for signal detection and management.
One year after the implementation of Commission Implementing Regulation (EU) 2025/1466, this workshop will examine key lessons learned, implementation challenges, and emerging opportunities in pharmacovigilance operations. Through expert insights and interactive discussions, participants will explore compliance strategies, operational adaptations, and approaches to maintaining patient safety in the evolving regulatory landscape. Featured presenters:
- Elena Alcaraz , EU/UK QPPV, Strategic Advisor | PrimeVigilance
- Mercedina del Papa, EU/UK QPPV, Strategic Advisor | PrimeVigilance
The session that traditionally closes the EU PV Congress is also one of its most important. Compliance -and the successful outcome of audits and inspections- represents the true โlicense to operateโ in pharmacovigilance and across the pharmaceutical industry.
Scientific Advisory Group 2026
Felix Arellano
Owner | Arellano Risk Management, GmbH, Switzerland
Ayman Ayoub
Vice President Safety Evaluation and Risk Management | GSK
Mattia Calissano
VP, Medical | SSI Strategy
Gian Nicola Castiglione
Pharmacovigilance Consultant, SIMeF ETS Board member, Past Head of Global Pharmacovigilance and EU-UK QPPV, Pharmacovigilance trainer
Manuela Casula
Associate Professor at Department of Pharmacological and Biomolecular Sciences | University of Milan
Mircea Ciuca
Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance
Giovanni Furlan
Head Medical Safety Operations | Sandoz
Calin A. Lungu
DDCS S.A., CEO
Hrvoje Maฤek
VP Pharmacovigilance Services | Clingen
Valentina Mancini
Head of Drug Safety, QPPV | Shionogi Europe
Arduino Mangoni
Strategic Professor in Clinical Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
Jan Petracek
CEO |ย iVigee, Director | Institute of Pharmacovigilance
Marco Sardella
Chief Pharmacovigilance Officer & EU-UK QPPV| ADIENNE Pharma & Biotech – Chairperson of the Congress
Ivana ล utalo
Innovative Products, Business Unit Lead / EU QPPV / LCPPV Croatia | PrimeVigilance Ltd.
Elena Prokofyeva
Head of Clinical Trial Safety Unit, Department of Pharmacovigilance, DG POST | FAMHP – Belgium
Sophia Trantza
Senior Pharmacovigilance Expert, former PRAC Member Greece
SPEAKERS 2026 IN PROGRESS
Ana Sofia Martins
PRAC Member | INFARMED, I.P. – Portugal
Elena Giovani
Head of the GVP Inspection Office | AIFA (Tbc)
Amelia Cupelli
Pharmacologist, Italian Medicines Agency (AIFA), EMA PRAC Member, Italy
Pilar Rayรณn
PRAC – AEMPS Spain
Lembit Rรคgo
Secretary-General | Council for International Organizations of Medical Sciences (CIOMS) – Switzerland
Aurora Marรญa Rojo Sanchรญs
Head of GCP &GVP Inspectorate | Spanish Agency of Medicines and Medical Devices (AEMPS)
David Sullivan
Vigilance Collaborations Specialist | MHRA
Ursula Kirchmayer
Pharmacoepidemiologist at the Department of Epidemiology | Lazio regional health service
Fazil Afzal
Senior Medical Assessor at Medicines and Healthcare products Regulatory Agency (MHRA) – Uk (tbc)
Michelle English
Good Clinical Practice and Pharmacovigilance Inspector with the Health Products Regulatory Authority – Ireland
Claudia Schaffer
Head of ICSR Management | Merck Healthcare KGaA – Germany
Oanh Dang
Regulatory Science and Applied Research Lead | Food and Drug Administration (FDA) – USA
Marko Korenjak
President of the European Liver Patients ( ELPA), member of HMA management board of EMA – Slovenia
Maia Uuskรผla
Head of the Department of Post-Authorisation Safety | State Agency of Medicines, Estonia
Zane Neikena
EMA PRAC Member from Latvia, Pharmacovigilance expert
Jens-Ulrich Stegmann
Senior Vice President, Head Clinical Safety and Pharmacovigilance and EU QPPV | GSK – Belgium
Jonathan Sutch
Principal Technical Specialist & Scheme Manager | BSI Group – UK
Axelle Mutezinkwano
Pharmacovigilance Analyst Team Lead | Rwanda Food and Drugs Authority
Annalisa Capuano
Full Professor of Pharmacology – Department of Experimental Medicine |ย University of Campania โL. Vanvitelliโ – Italy
Kaori Nomura
Associate Professor | Fukushima Medical University – Japan
Andrew Bate
VP, Head of Safety Innovation & Analytics | GSK – Uk
Salvo Leone
General Director | Patientโs Association AMICI, Italy
Emanuele Lettieri
Full Professor | Politecnico of Milan, Italy
Margherita D'Antuono
Deputy Chief Manager – QPPV | Piramal Critical Care
Vicky Edwards
Vice President, Cross Therapeutic Area Safety Science, Global Patient Safety| Abbvie – UK
Anna Lombardo
Researcher | Istituto di Ricerche Farmacologiche Mario Negri IRCCS – Italy
Giovanna Paolone
Associate Professor of Pharmacology – Department of diagnostics and public health | University of Verona – Italy
Flavia Meyer
Researcher / Pharmacoepidemiology and Pharmacosurveillance Unit, National Centerm for Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy
Emanuela Corsini
Professor of Toxicology at Department of Pharmacological and Biomolecular Sciences โRodolfo Paoletti’ | University of Milan
Barbara De Bernardi
EU & UK Pharmacovigilance Qualified Person, VP, Head of Global QPPV Office Worldwide Medical & Safety | Pfizer – Italy
Helaine Capucho
Access Director | Interfarma – Brazil
Ahmed Diaa Eldin
CEO | Baupharma – Czech Republic
Josรฉ Alberto Ayala Ortiz
CEO, QPPV, Pharmacovigilance consultant | PVpharm
Marie-Laure Kurzinger
Associate VP, Head of Pharmacoepidemiology -General Medicines, Pharmacovigilance and Patient Safety | Sanofi – France
Rajat Mohindra
Principal Medical Director Personalized Healthcare Safety | F.Hoffmann – La Roche – Switzerland
Adrian Roth
Principal Scientific Director Precision Safety | Roche – Switzerland
Ilaria Grisoni
Exec. Dir., Head of International QPPV Office, EEA QPPV | Jazz Pharmaceuticals – Italy
Michael Von Forstner
Managing Director | Mesa Laubela Consulting – Switzerland
Yiannoula Koulla
Patient Expert, Member of the EMA PRAC
Klaudija Marijanovic Barac
Associate VP, EU QPPV Deputy | Eli Lilly Hrvatska d.o.o. – Croatia
Daniela Gramaglia
Associate Director Medical Device Safety | Bayer
Alberto Gramaccioli
Director of Quality Management and Inspection | Pfizer
Maria Beatrice Panico
Chief Medical Officer | Scendea – UK
Maddalena Lino
Safety Risk Lead, Sr Director | Pfizer – Italy
Daniela Marcozzi
Head of Corporate Clinical Safety, Pharmacovigilance and R&D Compliance – Company Representative for Competent Health Authorities | Fidia Farmaceutici – Italy
Mercedina del Papa
EU QPPV, UK QPPV, Strategic Advisor | PrimeVigilance
Elena Alcaraz
EU QPPV, UK QPPV, Strategic Advisor | PrimeVigilance
Bogdana Ioana Balas
Group Medical Director | F. Hoffmann – La Roche Ltd – Switzerland
Lucia Biagiotti
Safety & Vigilance – BU Director | PL Italia
Alexandru Mihai Bica
Head of Early Development Safety | CSL Behring – Germany
Mehmet Burcu
Sr. Director, Epidemiology | Merck & Co., Inc., Rahway –ย NJ, USA
Marie-Pierre Caby-Tosi
Executive Director, EEA/UK QPPV, Head of EMEA PV Clinical Safety & Pharmacovigilance | Moderna – France
Katerina Georgousaki
Regulatory Affairs Manager | ELAIS-Unilever Hellas S.A. – Greece
Ramona Grigorescu
Senior Medical Monitor | Danone – Holland
Sadia Halim
SERM Medical Director | GSK – Uk
Mohamed Ali Kotal
EU-QPPV & Head QPPV Office | Sandoz – Germany
Daniel Hyde
Associate Director, Pharmacovigilance Operations | Clinigen – UK
Wojciech Maseลbas
SERM Medical Director | Gsk – Poland
James Milligan
Vice President | SSI – UK
Darmendra Ramcharran
Sr Director, Safety & Quantitative Innovation | GSK – USA
Hendrik ล uvalov
PhD Student in Health Informatics | University of Tartu – Estonia
Alina Tudor
Senior Director, Pharmacovigilance | Kyowa Kirin International plc. – UK
Hans-Joerg Roemming
Executive Director, Head of RQS Information, Systems & Insights | Merck Healthcare KGaA – Germany
Aya Anis
MSc. PV. Diploma, Egypt QPPV – PV Director | Baupharma – Czech Republic
Zaina Bakir
PharmD, RPh, Certified PV Professional, KSA QPPV & PV Director | Baupharma – Czech Republic
Serban Ghiorghiu
Vice President, Clinical Development, Late Development Oncology R&D | AstraZeneca
Anette Kirstine Stark
Independent Scientific Expert | PRAC, EMA – Denmark
Natasha Mihajlovic
Chief AI Compliance Officer | Yeza.ai; Managing Director | NostraPharma
MEDIA PARTNER/COLLABORATIONS/SPONSORS 2026 - in progress
Sage Publishing
Scientific Media Partner
Sage Publishing
Scientific Media Partner
Published by Sage Publishing, Therapeutic Advances in Drug Safety (Impact Factor: 3.4) is an international peer-reviewed Open Access journal, delivering the highest quality original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.
As the official Media Partner of the European Pharmacovigilance Congress, Therapeutic Advances in Drug Safety will be publishing an online abstract supplement which will be free to access online.
For more information:
E-mail: shasha.sharief@sagepub.co.uk
Twitter: @TADrugSafety
Visita il sito »
Institute of Pharmacovigilance
Collaboration
Institute of Pharmacovigilance
Collaboration
Founded in 2015, the Institute of Pharmacovigilance (IPV) is a not-for-profit, non-governmental global organization with a clear goal โ to elevate the pharmacovigilance industry by competency and seniority certification.
In 2020, IPV partnered with the International Society of Pharmacovigilance (ISoP) to develop the Global Pharmacovigilance Professional Certification (GPPC), creating a globally recognized standard for PV professionals. The certification works with competency standards including knowledge, skills and attitudes suitable for every role in pharmacovigilance.
Committed to continuous innovation, IPV regularly updates its programs to reflect the latest advancements, ensuring certified professionals have practical knowledge and skills they can apply in their jobs immediately.
Visita il sito »
Universitร degli Studi di Milano - Dipartimento di Scienze Farmacologiche e Biomolecolari
Scientific Partnership
Universitร degli Studi di Milano - Dipartimento di Scienze Farmacologiche e Biomolecolari
Scientific Partnership
Ilย Dipartimento di Scienze Farmacologiche e Biomolecolari “Rodolfo Paoletti”ย (DiSFeB), nominato Dipartimento di Eccellenza 2023-2027, nasce il 27 aprile 2012 dallโaggregazione di settori scientifico disciplinari con comuni interessi di ricerca scientifica di alto profilo, e assicura unโequilibrata valorizzazione di tutti i settori scientifico-disciplinari che vi afferiscono. Il DiSFeB mira a consolidare il suo ruolo chiave nelleโฏattivitร didattiche eโฏdiโฏricerca, e a rinnovare il suo portfolio diโฏcompetenze tecnico-scientifiche a beneficio della societร , contribuendo nel campo delle scienze biologiche applicate alla salute umana, alla prevenzione delle malattie e alla progettazione di farmaci e prodotti per la salute.
Visita il sito »
Baupharma
Silver Sponsor
Baupharma
Silver Sponsor
Baupharma, headquartered in Prague, is a premier pharmaceutical service provider with over 25 years of industry experience. Our international team offers comprehensive servicesโincluding pharmacovigilance, regulatory affairs, medical writing, batch release and distribution, translations, and clinical researchโacross the EU, MENA region, CIS, Africa, USA, LATAM, and beyond. With offices in Czech Republic, Saudi Arabia, UAE and Egypt, we ensure efficient project management and collaboration, delivering tailored solutions that meet the unique needs of each market.
Visita il sito »
Eureka InfoMed
Exhibitor
Eureka InfoMed
Exhibitor
Eureka InfoMed โ Your Team to Growth
We make Pharmacovigilance work โ reliably, efficiently, and with purpose.
Eureka InfoMed is a trusted partner delivering endโtoโend operational support across Pharmacovigilance, Medical Information, and Quality.
We combine operational excellence with a pragmatic, partnershipโdriven approach to turn complexity into compliant, efficient, and scalable processes.
Within these areas, we support pharmaceutical and biotech companies through services including Quality Management Systems, Quality Assurance activities, and Pharmacovigilance audits, helping them strengthen compliance, mitigate risk, and optimize operations in a constantly evolving regulatory environment.
We donโt believe in oneโsizeโfitsโall solutions.
Whether you are building, strengthening, or transforming your Pharmacovigilance organization, Eureka InfoMed works side by side with you, acting as an extension of your team and providing expertise that grows with your needs and strategic objectives.
Visita il sito »
Insuvia
Exhibitor
Insuvia
Exhibitor
Insuvia is designed to act as a pharmacovigilance unit for pharmaceutical companies in those countries and regions, where they have no internal structures or decide to focus their resources on commercial activities. In this context, we provide the regional EU and country-level expertise to solve all pharmacovigilance challenges that pharmaceutical companies encounter while commercializing their products.
Visita il sito »
iVigee
Platinum Sponsor
iVigee
Platinum Sponsor
iVigee is a leading pharmacovigilance services and technology company focused on creating simple, powerful, and elegant drug safety solutions that span the entire drug safety life cycle.
We combine years of experience with the latest innovative AI technologies to create the โinstant pharmacovigilance departmentโ, deployable anywhere, on-demand.
Our teams support clients around the world with progressive pharmacovigilance and data management requirements from our strategic bases in Central Europe and the US East Coast.
iVigee: Simple. Powerful. Elegant.
Visita il sito »
MakingLife
Media Partner
MakingLife
Media Partner
MakingLife is a publishing house and communications agency specializing in the pharmaceutical sector. It combines editorial expertise with strategic communication to provide high-value scientific content for B2B audiences. Through magazines (paper and digital) and digital platforms, such as the MakingConnect community, MakingLife supports pharmaceutical companies and their supply chain in improving visibility and promoting innovation. Its multidisciplinary team combines scientific accuracy, creative storytelling and market knowledge to design communication tools. Furthermore, through MakingEducation, MakingLife offers its customers a training service dedicated to the pharma sector.
Visita il sito »
Max Application
Exhibitor
Max Application
Exhibitor
SafetyDrugs, developed by Max Application, an Abacus company, is a pharmacovigilance safety database managing the lifecycle of ICSRs from clinical trials and post-marketing sources. Designed in compliance with ICH E2B(R3), GVP and GDPR, it meets EMA, FDA and MHRA requirements. The platform enables automated case transmission and regulatory reporting (PSUR, PBRER, DSUR), ensuring data integrity, inspection readiness and full compliance. The offering is completed by the Business Intelligence module for Signal Detection and by the newly developed Chronisia, which automatically calculates regulatory deadlines (e.g. PSUR, RMP, MA renewal) enables task assignment and reduces risk of delays and non-compliance.
Visita il sito »
PrimeVigilance
Gold Plus Sponsor
PrimeVigilance
Gold Plus Sponsor
PrimeVigilance, an Ergomed company, has grown to become the leading Pharmacovigilance specialist company, delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from our operational hubs based in Europe, the USA, and Japan. Our extensive experience enables us to offer a comprehensive, top-quality, cost-effective, and innovative safety solution. Our flexible approach, tailor-made to work with clients, allows us to deliver the services that meet your clinical and post-marketing needs. PrimeVigilance provides pharmacovigilance solutions to over 300 clients who distribute their products worldwide. PrimeVigilance manages a global Pharmacovigilance system with a choice of leading drug safety databases, stretching to more than 100 countries.
Visita il sito »
ProductLife Group
Exhibitor
ProductLife Group
Exhibitor
ProductLife Groupโs mission is to improve human health by delivering regulatory compliance services that support the safe and effective use of healthcare products and solutions.
For more than 30 years, PLG has supported clients throughout the entire product lifecycle, combining local expertise with a global reach spanning more than 150 countries. The Group provides consulting and outsourcing services across regulatory affairs, quality and compliance, market access, pharmacovigilance, and medical information, covering both established products and innovative therapeutics and diagnostics.
Committed to continuously improving the value delivered to patients and customers, PLG fosters long-term partnerships built on innovation, flexibility, and cost efficiency.
Visita il sito »
PVpharm
Gold Sponsor
PVpharm
Gold Sponsor
Pharmacovigilance, Clinical Safety, Regulatory and Quality Solutions for the pharmaceutical industry.
PVpharm provides services to Marketing Authorisation Holders, Sponsors of Clinical Trials and other Life science service providers.
Our objective is to help the Pharmaceutical industry to comply with Pharmacovigilance, Clinical safety, Regulatory and Quality requirements. We provide global, professional, quick, and flexible solutions to complex, specialized needs.
Our specialities include Pharmacovigilance and Clinical Safety services, Regulatory affairs, Medical Services, EU-QPPV and Local contact person for pharmacovigilance, Pharmacovigilance and GCP Audits, EudraVigilance compliance, CTIS support, Pharmacovigilance training, including EVWeb and XEVMPD (eXtended EudraVigilance Medicinal Product Dictionary) training, Signal Detection and Signal Management using EVDAS, IDMP implementation preparation, and data management.
We provide services for drugs, devices, veterinary, food supplements and cosmetics.
We do also provide GxP support and provide GMP specialized audits.
Visita il sito »
Diventa sponsor
Don’t miss the chance to be a European Pharmacovigilance Congress 2026 sponsor!
Contact us to learn about our sponsorship packages, you will have the opportunity to:
โข Deliver a talk in person or online
โข Conduct a parallel session during the day in Milan
โข Network and connect with your target customers
Check out our sponsorship opportunities here:ย Become EUPV Sponsor
Sede del congresso
Step 1
Onย November 18-19ย the event will beย VIRTUAL to grant you the possibility of joining the conference even from your office or home, wherever you may be. We have organized a true virtual location, a space where you will be able to:
- Follow the live streaming of the congress, listen to experts and opinion makers and be informed about latest trends and technological breakthroughs in drug safety
- Visit theย VIRTUAL EXHIBITION AREAย and all the stands of our sponsors
- Join Q&A times and round tables to discuss the current hot topics in the field
- Chat with our sponsors and learn about new technologies and services to ease your daily work and increase the performance
Step 2
Letโs finally meet face to face in Milan on December 3-4! A great chance to meet in person the EUPV experts and colleagues. A great chance to meet in person the EUPV experts and colleagues. The conference will be hosted in the wonderful spaces of NH Milano Congress Centre, in Assago, Milan.
NETWORKING APERITIVO December 3, 2026 (NH Milano Congress Centre, in Assago, Milan)
–> If you would like to attend the Networking Aperitivo, please save your spot here: Networking Aperitivo
PLEASE NOTE:
Ticket options labeled โ+ Visaโ are intended for participants who need to request a visa invitation letter in order to attend the event. If you need more information contact info@pharmaeducationcenter.it
Arrivare in aereo
From Malpensa Airport:
-
- take the bus to the central station, then the subway towards Assago Milanofiori Forum
- take the express train from Malpensa to the Cadorna station, then the Green subway in the direction of Assago Milanofiori Forum.
From Linate Airport:
take the bus to San Babila station, then the subway towards Assago Milanofiori Forum.
Arrivare in treno
From Centrale or Cadorna train station, take green line subway to Assago Milanofiori Forum.
Arrivare in tram
From Piazza del Duomo:
take the red subway line towards RHO FIERAMILANO and change at CADORNA. Take the green line towards ASSAGO MILANOFIORI FORUM and get off at the Assago Milanofiori Forum stop. Walk for about 7 minutes to reach the hotel.
Edizioni precedenti
Iscriviti alla conferenza
Face to Face (3-4/12/2026) | 450€ |
Virtual (18-19/11/2026) | 750€ |
Virtual + Face to Face (18-19/11/2026 and 3-4/12/2026) | 880€ |
Hospitals, universities and freelance professionals get a 40% discount to be applied to published prices.
If you would like to attend the NETWORKING APERITIVO, please save your spot here: Networking Aperitivo
Attendance to the event will be allowed upon receipt of payment.